Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 731 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR 38% of Recurrent Breast Cancers Have a Different HER2 Status than... May 25, 2021 10 Ways to Keep Your Family Safe from the Coronavirus Outbreak January 29, 2020 The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... July 8, 2024 Load more HOT NEWS Can Age Affect Response to Immune Checkpoint Inhibitors? New on NCI’s Websites for March 2019 Worse Survival Observed Among Patients Diagnosed with Cancer During the First... Trialling a new way to boost CAR T-cell therapy
